Article Finder
Browse our vast collection of articles. Simply select a category on the left and find a list of related articles on the right.
Article Category
Article Title
- High or Low Blood Pressure May Raise the Risk of Dementia
- How Alcohol Might Affect Your Dementia Risk
- The Hidden Costs of Alzheimer’s Disease
- Susceptible to Scams? It May Be an Early Sign of Alzheimer’s Disease
- Alzheimer’s Caregivers May Benefit from Happiness Training
- Giving Up the Guns When a Family Member Has Alzheimer’s
- Care Management Program Is Reducing Need for Anti-anxiety Medication and Visits to the Hospital/Emergency Room
- Talking to a Loved One With Alzheimer’s
- 10 Powerful Ways to Commemorate Alzheimer’s Awareness Month
- Making the Most of Mealtimes for People With Alzheimer’s
- FOR MORE ARTICLES CLICK HERE
- Depression Increases the Risk of Alzheimer’s Disease
- Poor Sleep Tied to Rise in Alzheimer’s Protein in Blood
- Air Pollution Tied to Alzheimer’s Brain Changes
- The Tau of Alzheimer’s
- Anemia Tied to Alzheimer’s Risk
- ‘Squeezed’ Blood Vessels in the Brain May Contribute to Alzheimer’s Onset
- Hormone Therapy for Prostate Cancer Tied to Alzheimer’s Disease Risk
- Lack of Deep Sleep Tied to Alzheimer’s Brain Changes
- Inflammation in Middle Age Tied to Thinking and Memory Problems Later
- Frailty May Increase Susceptibility to Alzheimer’s Disease
- FOR MORE ARTICLES CLICK HERE
- Take Your Blood Pressure Meds. It May Reduce Your Alzheimer’s Risk.
- Drug Company to Pursue Approval of Aducanumab, New Drug for Alzheimer’s
- Drugs May Not Be the Best Choice for Easing the Agitation of Alzheimer’s
- Alzheimer’s Drug May Lead to Life-Threatening Muscle Disease
- Opioid Painkillers Increase Pneumonia Risk in People With Alzheimer’s Disease
- Drug Companies Halt Trials of Aducanumab for Alzheimer’s Disease
- Diabetes Treatments May Help Ward Off Alzheimer’s Disease
- Can Mushrooms Help Your Memory?
- Buyer Beware: Dietary Supplement’s Won’t Cure Alzheimer’s Disease
- Experimental Drug, Fails to Benefit Alzheimer’s Patients
- FOR MORE ARTICLES CLICK HERE
- Obesity at Midlife Tied to Increased Dementia Risk
- Reading and Writing May Be Good for the Brain
- Ski Study Shows How Exercise May Aid the Brain
- How Light May Help People with Alzheimer’s Disease
- Trans Fats Tied to Increased Alzheimer’s Risk
- New Guidelines Urge a Healthy Lifestyle to Prevent Dementia
- At Genetic Risk for Alzheimer’s Disease? A Healthy Lifestyle May Help
- Exercise Can Help Keep the Brain ‘Young’
- Fighting Gum Disease May Aid in Fight Against Alzheimer’s Disease
- Brain Scans Aid in Management of Alzheimer’s Disease
- FOR MORE ARTICLES CLICK HERE
- A Rare Genetic Mutation May Protect Against Alzheimer’s
- Income Drops in Young Adulthood May Impair Brain Health
- Blood Test for Alzheimer’s Grows Closer
- Are We Getting Closer to an Alzheimer’s Vaccine?
- Why More Women Than Men Have Alzheimer’s Disease
- Scientists get a ‘total surprise’ and a promising new clue for how to cure Alzheimer’s
- Some 44 Million People Have Alzheimer’s Worldwide
- Nearly 14 Million Americans Will Have Alzheimer’s Disease by 2060
- Alzheimer’s Rates Could Double in Coming Decades
- Combining Care Program With Medication Reduces Alzheimer’s Symptoms By 750%
- FOR MORE ARTICLES CLICK HERE
- Lucretia V. Holden promoted to Executive Director at the Fisher Center
- The Fisher Center for Alzheimer’s Research Foundation Earns Coveted 4-Star Rating from Charity Navigator for the 8th Consecutive Year
- Fisher Center For Alzheimer’s Research Foundation Wins Fall 2018 Digital Health Awards®
- Fisher Center for Alzheimer’s Research Foundation Earns Gold Seal of Transparency from GuideStar
- The Fisher Center for Alzheimer’s Research Foundation Earns Coveted 4-Star Rating from Charity Navigator for the 7th Consecutive Year
- Hear Kent Karosen, President and CEO of the Fisher Center for Alzheimer’s Research Foundation, describe his new book and the power of art therapy
- Fisher Center Scientists link a Mutation That Protects Against the Development of Alzheimer’s Disease
- Newly Inducted Into the Basketball Hall of Fame, Shaquille O’Neal, Joins the Fisher Center for Alzheimer’s Research Foundation to Raise Funds for Groundbreaking Research in the Quest for a Cure
- Pat Summitt, legendary women’s basketball coach, dies at 64
- Celebrating the life of Nancy Reagan for her Impact on the Fight to end Alzheimer’s
- FOR MORE ARTICLES CLICK HERE
Skin Patch Approved for Treatment of Mild to Moderate Alzheimer’s
July 30, 2007
July 30, 2007
A skin patch that delivers small, continuous doses of the Alzheimer’s drug Exelon throughout the day was approved for sale in the United States earlier this month. It is expected to be available in pharmacies in the coming weeks.
The “Exelon Patch” contains the same medication, rivastigmine, that is has been available in capsule form since 2000 to treat mild to moderate Alzheimer’s. The medication is also available in a liquid form. The skin patch is replaced once a day and worn on the back, chest, or upper arm.
Various medications have been available as skin patches, which allow small and continuous doses of the drug to be absorbed through the skin, but this is the first such skin patch to be available for the treatment of Alzheimer’s disease.
According to the drug’s maker, Novartis Pharmaceuticals, the skin patch may be preferred by caregivers because it may be easier to apply than taking a pill. “The patch provides a visual reassurance for the caregiver that the patient is receiving their medication,” they note. Because it delivers a small and steady dose, it may also be less likely to produce upset stomach, nausea and vomiting than oral forms of the drug, the drug-makers say.
The Food and Drug Administration also approved the use of Exelon Patch in treating patients with mild to moderate dementia due to Parkinson’s disease. Parkinson’s disease is a chronic and progressive neurological condition that affects some 1.5 million people in the United States.
For more on the use of Exelon to treat Alzheimer’s, visit “Drug Facts: Exelon.”
By www.ALZinfo.org, The Alzheimer’s Information Site. Reviewed by William J. Netzer, Ph.D., Fisher Center for Alzheimer’s Research Foundation at The Rockefeller University.
